Pascal Touchon | Senior Vice President and Global Head Cell & Gene

Pascal Touchon, Senior Vice President and Global Head Cell & Gene, Novartis

Professional Background
Pascal Touchon is Senior Vice President, Global Head Cell & Gene and member of the Oncology Executive Committee. In this role, Pascal is responsible for leading a cross- functional and cross-divisional team in Cell & Gene Therapies, reporting to Elizabeth Barrett, CEO of Novartis Oncology.  His responsibilities cover clinical development, manufacturing, medical affairs, commercial activities and the development & execution of Novartis strategy in Cell & Gene Therapies in oncology. 
Prior to this Pascal was Senior Vice President and Global Head Oncology Strategy & Business Development. Pascal was responsible for Novartis Oncology early commercial strategy, portfolio management, BD&L, external collaborations, alliance management, disruptive technologies, Therapeutic Integrity & Established Medicines as well as global business activities in Cell & Gene Therapies.  He was also a Board member of Genoptix and then Navigate Biopharma Services Inc., a Novartis company dedicated to oncology clinical trials diagnostics, whose President was reporting to Pascal.
Prior to joining Novartis, Pascal was Senior Executive Vice President and Head of Business Development and Licensing for Servier, a private research-based pharmaceutical company, where he led the sourcing, evaluation, negotiation and closing of numerous partnerships with biotechs, pharmaceutical companies and academic institutions.
Prior to joining Novartis, Pascal has held positions in Research, Marketing and Sales, General Management and Business Development at various companies including Sanofi, Virbac, Glaxo, Glaxo-Wellcome and Servier. He has extensive international experience in leading marketing and commercial operations and as General Manager in France, Central & Eastern Europe, Northern Europe, Asia, Australia, Canada, and South Africa.
Education and Training
Pascal holds a Doctorate in Veterinary Medicine from Paul Sabatier University (Toulouse, France), a Diplôme d'Etudes Superieures Specialisees (DESS) in Management from Institut d’Administration des Entreprises (Toulouse, France) and an MBA from INSEAD (Fontainebleau, France).


World Immunotherapy Congress 2018, Day 1 @ 09:00

Novartis: CART Innovation Journey

  • From academic lab to FDA approval: a 5 yr journey
  • Tisagenleucleceul a transformative therapy in ALL and DLBCL
  • Key challenges for global access to patients
  • Future innovations in CART

World Immunotherapy Congress 2018, Day 1 @ 09:40

Senior-level panel: Immunotherapy strategies for oncology

  • Short 5 minute presentations outlining strategies developing immunotherapy for oncology, given by 6 high level representatives from differing company sizes
  • Panel discussion talking about how strategies for cancer immunotherapy differ between companies, and advantages and disadvantages for both
  • Top level speakers representing big pharma, large biotech and mid-sized biotech
last published: 15/Oct/18 14:45 GMT
last published: 15/Oct/18 14:45 GMT
last published: 15/Oct/18 14:45 GMT
last published: 15/Oct/18 14:45 GMT

back to speakers

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.

Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates